Thus, the biological and clinical effects of TP73 in breast cancer must be interpreted in the context of TP53 mutation status, since mutant p53 not only disrupts its own tumour-suppressive functions but also impairs p73 activity, potentially converting p73 from a tumour suppressor into a factor permissive of oncogenesis [12,15]. Here, TP53 is linked to breast cancer.